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included one of the three combinations:
eMF; modified Cooper regimen (CMFVP);
31 patients (19%), anthracycline-based
regimens (FAC and FEC); 16 patients
(10%) and 118 patients (71%).
Results: The objective response rate in
the entire group was 58%; 75% in patients
who developed grade 2-3 leukopenia
during induction chemotherapy, and 52%
in those who had no or grade 1 leukopenia
(p<0.01, multivariate analysis). No other
patient- or treatment-related factor
including age, performance status, T
stage, N stage, supraclavicular lymph
node involvement, inflammatory carcinoma
or chemotherapy regimen correlated with
response to chemotherapy. There was no
correlation between treatment-induced
leukopenia and overall survival.
Conclusions: These findings suggest a
relationship between chemotherapy-
induced leukopenia and tumour response
in patients with locally advanced breast
cancer. The prognostic impact of leuko-
penia is negligible.
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EFFICACY OF VARIOUS CHEMO-
THERAPY SCHEMES IN TREAT-
MENT OF ADVANCED MEDULLARY
THYROID CANCER
Roumiantsev P.O., Isaev P.A., lIyin A.A.,
Medvedev V.5.
Medical Radiological Research Center RAMS,
Obninsk, Russia
Aim. To evaluate an efficacy of various
chemotherapeutical combination in treat-
ment of advanced medullary thyroid
cancer (MTC).
'Materials and rnethods. Frorn2001 to
2002 year 7 patients with advanced MTC
were treated with chemotherapy. Mean
age was 42 years (range 22 -62). Mean
follow-up mean period was 16 months.
Scheme ZDF, 3 patients, included
Zavedos 5 mg/m2 i/v 1 - 3 day; Dacar-
bozine mg/m2 i/v 1-3 day; 5-Flourouracil
250 mg/m2 i/v permanent infusion during
3 days. Scheme HC, 3 patients, Holoxan
2.5 mg/m2 i/v 1 ? 5 days and Cisplatinum
100 mg/m2 i/v ? 1st day. Scheme VG,
1 patient, daily infusions of Vinorelbine
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30 mg/m2 on 1st day and Gemzar
1500 mg/m2 on 8th. Schemes repeated
every 3, three courses. Effectiveness was
assessed correspondingly to WHO criteria
(Geneva, 1979).
Results. All six patients who underwent
ZDF and HC combinations displayed
positive response. Partial regression
registered in two patients for each
combination and stabilization in another
one. Mean positive effect duration was
6 months in ZDF group and 12 months in
HC group. In single patient who underwent
VG combination was registered tumor
progression. Tumor markers dynamics
(TCT, CEA) during treatment did not
reflect tumor response. All chemotherapy
combinations were associated with nausea
and vomiting which successfully treated
with antiemetic drugs. ZDF scheme always
was associated with dermatitis and
phlebitis, and stomatitis in one case. HC
scheme caused neutropenia and
trombocytopenia in all patients.
Conclusions. Positive response was
observed in all six cases following usage
of ZDF and HC combinations. Partial
response registered in two of three cases
in each group and stabilization in others.
Both combinations should be recom-
mended for palliative treatment of MTC
patients. HC combination was slightly
more effective as well as more toxic.
Taking into consideration a high rate of
inoperable cases and unfourable behavior
of MTC it is essential to continue
evaluation and search of new effective
schemes of chemotherapy.
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TRASTUZUMAB - LEK BUDZAtCY
NADZIEJ~ CHORYCH NA RAKA
P'IERSI""; OPIS PRZYPADKU59:LET-
NIEJ CHOREJ LECZONEJ TRASTU-
ZUMABEM PRZEZ 28 MIESI~CY
Szczepanska M" Zatuski J.
Wielkopolskie Centrum Onkologii,
Oddziat Chemioterapii
Cel pracy - ukazanie dziatania trastuzu-
mabu - przeciwciata monoklonalnego
anty-HER, w kolejnym rzucie leczenia
zaawansowanego raka piersi, na przykta-
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